263 filings
Page 2 of 14
UPLOAD
ylln7a7c6tzrpiz 4q
26 Sep 23
Letter from SEC
12:00am
8-K
glvq0 fxn
18 Sep 23
Updated Phase 1 results selected for a poster presentation at ESMO 2023
7:05am
8-K
c5owxuo w1dzt0ium1ix
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
7:56pm
8-K
5202h65
8 Aug 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
7:15am
8-K
x4e23elpz60iblmka0zj
6 Jun 23
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
4:15pm
8-K
clhvh8pwe92n6
9 May 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
9:01am
8-K
pmyhew82q
12 Apr 23
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
7:02am
8-K
thpmjfaf65cl 5x
10 Mar 23
Submission of Matters to a Vote of Security Holders
12:50pm
8-K
6u4sbr
7 Feb 23
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
7:02am
8-K
8kdm6v bsi6j6pr0
13 Dec 22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2022 Fiscal Year
7:01am
8-K
yril99vd0w62ge
31 Oct 22
ESSA Provides an Update on its Clinical Collaboration with Janssen
7:11am
8-K
t0xf1ojs
26 Oct 22
Regulation FD Disclosure
7:33am
8-K
qlv6qaub5
13 Sep 22
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
5:02pm